A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
Unknown

Flash Digest: News i

By Daniel Etcovitch - Edited by Emily Chan Florida Judge Rules ...

hammer

Federal Circuit Flas

By Yuan Cao - Edited by Frederick Ding Mere Commercial Benefit ...

3293465641_b6c5081e87_q

Sixth Circuit Finds

By Filippo Raso – Edited by Ariane Moss Detroit Free Press, ...

free-speech

The EFF Challenges t

By Priyanka Nawathe – Edited by Kayla Haran 17 U.S.C § ...

Unknown

Flash Digest: News i

By Jaehwan Park - Edited by Kayla Haran Bipartisan Lawmakers Introduce ...